Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Timing of Cardio-Kidney Protection with SGLT2 Inhibitors
Added: 1 year ago Source:  Radcliffe Cardiology
AUTHOR: Jordan Rance; Special Editor: Greg GuilloryA new analysis sheds light on the timing of protection offered by SGLT2 inhibitors. Researchers conducted a cross-trial analysis using individual participant data from four large-scale randomized clinical trials: CANVAS (type 2 diabetes with high atherosclerotic risk, NCT01032629), CREDENCE (diabetic kidney disease, NCT02065791), DAPA-HF (heart… View more

Cardiovascular Renal Metabolic

Heart Failure
ACC 24 Late-Breaker Discussion: The RELIEVE-HF Trial
Author(s): Harriette Van Spall , Gregg Stone Added: 2 years ago
ACC 2024 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) welcomes Principal Investigator Dr Gregg Stone (Icahn School of Medicine at Mount Sinai, New York, NY, US) to discuss the REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure (NCT03499236) (V-Wave Ltd).The RELIEVE-HF trial aims to assess the safety and efficacy of a new device, the V-Wave… View more

Heart Failure
Hot Line Sessions Revealed for ESC Congress 2025
Added: 9 months ago Source:  ESC Congress 2025 Scientific Programme
Ten hot line sessions have been announced for ESC Congress 2025.The congress is set to take place from the 29th August to 1st September at IFEMA - Fiera de Madrid.Access the full programme here.Hot Line 1Friday 29th August, 11:00am – 12:00pm (CEST)POTCAST – a Randomized Controlled Trial of Arrhythmia prevention using targeted plasma potassium levels in ICD Patients – Presented by Christian… View more

Intervention

Vascular Disease and Surgery
Guideline-directed Medical Therapy is the Most Effective Decongestion
Author(s): Jelena Celutkiene , Alexandre Mebazaa , Jan Biegus , et al Added: 1 year ago

Heart Failure
THT 25: The RELIEVE-HF Study
Author(s): Gregg Stone Added: 1 year ago
THT Conference 2025 - Outcomes after heart failure patients were treated with an interatrial shunt show heart failure with reduced ejection fraction (HFrEF) patients had further benefit compared to heart failure with preserved ejection fraction (HFpEF) patients. The study's prediction model revealed four independent predictors of two-year adverse outcomes in HFrEF patients treated with medical… View more

Heart Failure
Research Area(s) / Expertise: Job title: Interventional Cardiologist
Dr Paul Sorajja is an Interventional Cardiologist at the Banner Health in Phoenix, Arizona.Dr Sorajja's clinical practice specialises in interventional cardiology, with a focus on catheter-based therapy of valvular and structural heart disease. He was part of the team that performed the first transcatheter mitral valve replacement in the US for a patient with native mitral regurgitation in 2015,… View more
Research Area(s) / Expertise:
HFA 24: MONITOR-HF Subgroup Analysis
Author(s): Jasper J Brugts Added: 1 year ago
HFA 24 - We are joined by Dr Jasper J Brugts (Erasmus University Medical Centre, NL) to discuss the findings of a predefined subgroup analysis of the MONITOR-HF study (NTR7672).MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation,… View more

Heart Failure
VICTOR Trial: Vericiguat Shows No Benefit for Primary Endpoint in Stable HFrEF
Added: 7 months ago Source:  Radcliffe Cardiology
Results from the Phase III VICTOR trial, presented at the European Society of Cardiology (ESC) Congress 2025 and published in The Lancet, show that vericiguat did not meet its primary endpoint in patients with chronic, stable heart failure with reduced ejection fraction (HFrEF).¹˒²Vericiguat is an oral, once-daily stimulator of soluble guanylate cyclase (sGC), an enzyme in the nitric oxide… View more

Guidelines & Statements

Heart Failure
RSV Vaccine Effective in Patients With ASCVD: DAN-RSV
Added: 5 months ago Source:  Radcliffe Cardiology
A prespecified secondary analysis of the DAN-RSV trial has found that a bivalent respiratory syncytial virus (RSV) vaccine is similarly effective against respiratory and cardiovascular outcomes in older adults, regardless of pre-existing atherosclerotic cardiovascular disease (ASCVD).¹The bivalent RSV prefusion F protein-based (RSVpreF) vaccine contains stabilised prefusion F glycoproteins from… View more

Demographic

Heart Failure